> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alcon Sales Rise 5% On Both Bases As It Narrows Its 2026 Outlook
- URL: https://www.bullished.co/alcon-sales-rise-5-on-both-bases-as-it-narrows-its-2026-outlook-ccc9c061/
- Published: 2026-11-10T21:41:05.000Z
- Updated: 2026-11-10T21:41:05.000Z
- Description: The eye-care company increased expected annual efficiency savings to approximately $130 million from approximately $100 million.
- Author: Matteo Parrino
- Tags: SEC Filings, ALC, Industry: Healthcare

Alcon, which makes eye-care products for surgeons, professionals and consumers, reported third-quarter sales growth of [5% on both](https://www.sec.gov/Archives/edgar/data/1167379/000116737926000033/q32026pressrelease.htm?ref=bullished.co) a reported and currency-neutral basis Tuesday, reaching $2.7 billion. Its earnings release also narrowed the 2026 outlook and increased the savings it expects from expanded efficiency measures.

## A Narrower Forecast, Bigger Savings

Alcon now expects approximately 6% currency-neutral sales growth for 2026, within its August range of 5%–7%. It tightened expected currency-neutral core diluted earnings-per-share growth to 12%–14% from 12%–15%, and core operating-margin improvement to [1.0–1.5 percentage points](https://www.sec.gov/Archives/edgar/data/1167379/000116737926000033/q32026pressrelease.htm?ref=bullished.co) from 0.9–1.9 percentage points.

The company estimates approximately $230 million in total costs for the efficiency effort, which it announced on February 24, 2026 and expanded in November. Expected annual savings increased to approximately $130 million from approximately $100 million; Alcon expects the additional savings to help offset inflation and still plans to finish implementation in 2026.

Alcon Chief Executive Officer David J. Endicott said the company remains on course for its objectives, “despite some specific areas of [competitive pressure](https://www.sec.gov/Archives/edgar/data/1167379/000116737926000033/q32026pressrelease.htm?ref=bullished.co).”

## Implantables Slip While Equipment Grows

Surgical sales increased 4% to $1.5 billion, while Vision Care sales grew 6% to $1.2 billion, with both growth rates identical on reported and currency-neutral bases. Surgical supplies replacement lenses, instruments and equipment for eye procedures; Vision Care sells contact lenses and eye-health products.

Implantables sales fell 2% to $422 million on both bases. Alcon attributed the decline in artificial replacement lenses to U.S. competition, partly offset by PanOptix Pro and international growth. Consumables grew 6% to $789 million, while equipment and other sales rose 11% to $269 million; the company credited equipment launches including Unity and Valeda.

Contact-lens sales rose 4% reported, or 5% currency-neutral, to $737 million. Alcon credited premium-product mix and price increases, partly offset by older products. Ocular-health sales rose 8% on both bases to $500 million, with Tryptyr and Systane dry-eye products contributing to growth.

The Neurotech Pharmaceuticals acquisition announced in October expanded Alcon's retinal portfolio with ENCELTO, an FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, a retinal disease.

## Tariff Refunds Help Quarterly Earnings

Core diluted earnings per share rose 15% on both bases to $0.91 from $0.79\. This non-IFRS measure excludes items including intangible-asset amortization and efficiency costs. Diluted earnings per share rose to $0.54 from $0.48, up 13% reported and 14% currency-neutral.

Operating income increased 15% on both bases to $381 million, and operating margin reached 14.0% from 12.8%. The quarter included $58 million in tariff refunds, manufacturing efficiencies and lower amortization, alongside efficiency charges and higher sales and marketing spending. Alcon expects approximately $40 million in full-year tariff costs after mitigation and refunds.

For the first nine months, sales rose 7% reported and 6% currency-neutral to $8.2 billion. Diluted earnings per share fell to $0.92 from $1.53, primarily because of an approximately $287 million post-tax non-cash charge for discontinued PowerVision programs and efficiency costs. Core diluted earnings per share increased to $2.60 from $2.29.

Nine-month operating cash flow reached $1.7 billion from $1.6 billion. Alcon returned $748 million through dividends and buybacks over that period, including $210 million in third-quarter repurchases. Its market value was $36.3 billion at Tuesday's close.

Alcon is scheduled to discuss the results on its Wednesday earnings call at 8:00 a.m. Eastern Time.

### Sources

- [Form 6-K — Ad Hoc Announcement Pursuant to Art. 53 LR](https://www.sec.gov/Archives/edgar/data/1167379/000116737926000033/q32026pressrelease.htm?ref=bullished.co) — SEC EDGAR